Hca Healthcare Inc (HCA) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket
 


Hca Healthcare Inc   (NYSE: HCA)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare


Hca Healthcare Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Hca Healthcare Inc's ROI in the first quarter of 2026?
Hca Healthcare Inc achieved a return on average invested assets (ROI) of 19.22 % in its first quarter of 2026, this is above HCA's average return on investment of 12.67%.
Hca Healthcare Inc s investments during the 12 months ending in the first quarter of 2026 are valued at $40 billion

Despite the deterioration in its net income, company has improved ROI compared to the fourth quarter of 2025.

Within the Healthcare sector 64 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 337 to 358.

Definition and Formula of Return on Investment



Return On Investment (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM -3.34 % 0.37 % 0.82 % 3.7 % 3.78 %
Y / Y Net Income Change TTM 16.98 % 16.9 % 46.95 % 97.31 % 270.7 %
Investment (TTM) in Millions 39,838 42,088 39,418 41,297 43,700
Return On Investment (TTM) 19.22 % 18.7 % 17.56 % 16.3 % 15.88 %
HCA's Overall Ranking # 358 # 337 # 405 # 386 # 390
Seq. Investment Change TTM -2.32 % 0.09 % -1.55 % 0.42 % 1.44 %
Seq. Net Income Change TTM 0.41 % 6.53 % 6.12 % 3.05 % 0.35 %
Net Income (TTM) in Millions 7,814 7,782 7,305 6,884 6,680




Return On Investment HCA's Ranking
Within: No.
Industry # 2
Sector # 65
Overall # 358

Return On Investment Statistics
High Average Low
18.54 %
12.67 %
7.86 %
(Mar 31 2026)   (Sep 30 2013)



  News about Hca Healthcare Inc Return on Investment ROI

HCA Healthcare Appoints Dr. Monique Butler to Drive Graduate Medical Education Strategy Amidst Strong Financial Performance

March 12, 2024


Introduction
NASHVILLE, Tenn. – HCA Healthcare, Inc., a prominent healthcare provider in the United States, recently announced the appointment of Dr. Monique Butler as the President of Graduate Medical Education (GME), effective March 1, 2024. This strategic move comes at a time when HCA Healthcare is experiencing a remarkable return on investment, showcasing the company s commitment to enhancing its healthcare education sector.
Transition in Leadership
Dr. Butler s appointment comes as Dr. Bruce Deighton, the former president of GME, is set to retire from HCA Healthcare later in 2024. As Dr. Deighton s successor, Dr. Butler will be responsible for overseeing the enterprise-wide leadership, strategy, quality, and operations of the GME portfolio within HCA Healthcare.

HCA Healthcare Strengthens Leadership Team with Promotion of Michael R. McAlevey as Executive VP & Chief Legal and Administrative Officer, Bolstering Operational Efficiency and Risk Management Practices.

February 13, 2024

HCA Healthcare Promotes Michael R. McAlevey to Executive VP and Chief Legal and Administrative Officer, Restructures Senior Leadership Team to Enhance Operational Efficiency and Risk Management
NASHVILLE, Tenn. - In a strategic move to strengthen its leadership team and optimize operational effectiveness, HCA Healthcare, Inc. (NYSE:HCA), a renowned healthcare provider in the United States, has announced the promotion of Michael R. McAlevey to the position of Executive Vice President and Chief Legal and Administrative Officer. Currently serving as Senior Vice President and Chief Legal Officer, McAlevey s remarkable contributions since joining HCA Healthcare in 2022 from General Electric Company have positioned him as the ideal candidate for this expanded role.
His elevation to this executive position reflects the company s commitment to ensuring robust legal and administrative practices across its vast network. In his new capacity, McAlevey will spearhead a consolidated organization aimed at effectively managing enterprise risk while fostering stronger external affairs. This realignment is expected to streamline operations, facilitate seamless coordination, and enhance HCA Healthcare s ability to navigate the evolving healthcare landscape, ultimately benefiting patients and stakeholders alike.

HCA Healthcare Appoints Tech Visionary to Lead Digital Transformation for Enhanced Patient Care

February 5, 2024

HCA Healthcare Appoints New Chief Information Officer to Lead Technological Advancements
Nashville, Tenn - HCA Healthcare, Inc., a leading healthcare provider in the United States, has announced the appointment of Chad Wasserman as the senior vice president and chief information officer, effective from February 1, 2024. Wasserman, a nearly 30-year veteran of the company, will assume the role previously held by P. Martin Marty Paslick, who is retiring after an incredible 38-year journey with HCA Healthcare.
HCA Healthcare, known for its commitment to delivering high-quality patient care and leveraging technology to drive advancements in healthcare, has chosen Wasserman to lead a team of more than 6,700 colleagues in the Information Technology department. With his extensive experience and expertise, Wasserman is expected to guide HCA Healthcare s digital transformation and optimize the use of technology to deliver exceptional outcomes for patients and providers alike.






Financial Statements
Hca Healthcare Inc's I. Quarter Investments $ 39,838 Millions HCA's Balance sheet
Hca Healthcare Inc's I. Quarter Income $ 1,857 Millions Quarterly HCA's Income Statement
HCA's Income by Division See HCA's Income by Division


HCA Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 42,088 41,942 41,063 40,335 43,582
Y / Y Investment Growth 0.35 % 2.14 % 1.8 % -7.45 % 6.02 %
Net Income in Millions 7,782 6,657 6,091 6,834 7,721
Y / Y Net Income Growth 16.9 % 9.29 % -10.87 % -11.49 % 76 %
Annual Return On Investment 18.49 % 15.87 % 14.83 % 16.94 % 17.72 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 18.49 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Healthcare Facilities Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
HCA's Roi Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for HCA's Competitors
Subscribers only: Roi for Hca Healthcare Inc's Suppliers
Subscribers only: Return On Investment for HCA's Customers

Other Ratios
HCA's Roa HCA's Inventory Turnover Ratio HCA's Growth Rates HCA's Dividend Statistics
HCA's Profitability Ratios HCA's Asset Turnover Ratio HCA's Dividend Growth
HCA's Roe HCA's Valuation Ratios HCA's Financial Strength Ratios HCA's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Vaxart Inc   51.45 %
Escalon Medical Corp   51.07 %
Tg Therapeutics Inc   50.62 %
Zevra Therapeutics Inc   50.45 %
Idexx Laboratories Inc  50.05 %
Theravance Biopharma inc   43.85 %
Elite Pharmaceuticals Inc   43.22 %
Dariohealth Corp   40.59 %
Innoviva Inc   36.71 %
Indivior Pharmaceuticals Inc   36.55 %
Eli Lilly And Company  36.13 %
Abeona Therapeutics Inc   35.03 %
Lifemd Inc   34.80 %
Acadia Pharmaceuticals Inc   34.03 %
Mettler toledo International Inc   33.62 %
Adma Biologics Inc   30.38 %
Medpace Holdings Inc   30.34 %
Spero Therapeutics Inc   29.59 %
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %


Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.